Hernández-Alcaraz M, Dueñas-Arias JE

Language: Spanish
References: 19
Page: 170-175
PDF size: 276.81 Kb.

ABSTRACT

Introduction: The BCR-ABL fusion oncogene, a product of the Philadelphia chromosome t(9; 22), is relatively rare in children with acute lymphoblastic leukemia (ALL). Its presence is indicative of a poor prognosis. Objective: To determine the frequency of Philadelphia chromosome in children with ALL at the Pediatric Hospital of Sinaloa, Mexico. Material and methods: Nine-year records (2008-2017) of RT-PCR experiments for BCR-ABL of patients diagnosed with ALL were reviewed. Results: Of 138 patients with ALL, three Philadelphia chromosome positive patients (2.17%) were identified. These three patients were male, aged two to eight years, and were classified as having high-risk ALL. Although they have presented relapses, currently all three are alive and remain in treatment. Conclusion: The frequency of 2.17% of the Philadelphia chromosome in children with ALL that we found in this study, is similar to the figures described in other countries.

REFERENCES

1. Jiménez-Morales S, Hidalgo-Miranda A, Ramírez-Bello J. Leucemia linfoblástica aguda infantil: una aproximación genómica. Bol Med Hosp Infant Mex. 2017; 74(1): 13-26.

2. Jha S, Kumar D, Kaul JM, Singh T, Dubey AP. Cytogenetic pattern profiling in cases of Acute Lymphoblastic Leukemia in pediatric age group. J Anat Soc India. 2017; 66(1): 48-53.

3. Gallegos-Arreola MP, Borjas-Gutiérrez C, Zúñiga-González GM, Figuera LE, Puebla-Pérez AM, García-González JR. Pathophysiology of acute lymphoblastic leukemia. In: Mejía-Aranguré JM. Clinical epidemiology of acute lymphoblastic leukemia-from the molecules to the clinic. Rijeka, Croatia: InTechOpen; 2013, pp. 48-50.

4. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29(5): 551-565.

5. Liang DC, Yang CP, Lin DT, Hung IJ, Lin KH, Chen JS et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2): 397-405.

6. Mikhail FM, Serry KA, Hatem N, Mourad ZI, Farawela HM, El Kaffash DM et al. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia. 2002; 16 (4): 658-568.

7. Verduzco-Rodríguez L, Verduzco-Aguirre HC, López-Ariza B. Leucemia linfoblástica aguda hiperdiploide en niños. Revista de Hematología. 2012; 13: 172-176.

8. Bekker-Méndez VC, Miranda-Peralta E, Núñez-Enríquez JC, Olarte-Carrillo I, Guerra-Castillo FX, Pompa-Mera EN et al. Prevalence of gene rearrangements in Mexican children with acute lymphoblastic leukemia: a population study-report from the Mexican Interinstitutional Group for the identification of the causes of childhood leukemia. Biomed Res Int. 2014; 2014: 210560.

9. Lepe-Zúñiga JL, Jerónimo-López FJ, Hernández-Orantes JG. Características citopatológicas de la leucemia aguda en el Hospital de Especialidades Pediátricas de Chiapas, México. Bol Med Hosp Infant Mex. 2017; 74(2): 122-133.

10. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). Blood. 2007; 109(3): 926-935.

11. Chow EJ, Puumala SE, Mueller BA, Carozza SE, Fox EE, Horel S et al. Childhood cancer in relation to parental race and ethnicity: a 5-state pooled analysis. Cancer. 2010; 116(12): 3045-3053.

12. Bhatia S, Sather HN, Heerema NA, Trigg ME, Gaynon PS, Robison LL. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. Blood. 2002; 100(6): 1957-1964.

13. Aldrich MC, Zhang L, Wiemels JL, Ma X, Loh ML, Metayer C et al. Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California. Cancer Epidemiol Biomarkers Prev. 2006; 15(3): 578-581.

14. Lim JYS, Bhatia S, Robison LL, Yang JJ. Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia. Cancer. 2014; 120(7): 955-962.

15. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J Clin Oncol. 2012; 30(14): 1663-1669.

16. Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology. 2011; 25(4): 328-335.

17. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012; 13(9): 936-945.

18. Shen S, Chen X, Cai J, Yu J, Gao J, Hu S et al. Effect of dasatinib vs imatinib in the treatment of pediatric philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020; 6(3): 358-366.

19. Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A et al. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol. 2018; 5(12): e641-652.